People living with multiple sclerosis (MS) in the European Union could receive timelier access to safer and more efficient therapies. They could also become important partners in the regulation and pricing of medicines.

The key to turning these possible scenarios into reality is the better exploitation of Real World Evidence data.

For more details on the outcomes and CALL to Action, please read the EMSP Event Report

real world data EP event